| Click for the Finfacts Ireland Portal Homepage |

Finfacts Business News Centre

 Irish Economy
 EU Economy
 US Economy
 UK Economy
 Global Economy
 Asia Economy


How to use our RSS feed

Follow Finfacts on Twitter

Web Finfacts

See Search Box lower down this column for searches of Finfacts news pages. Where there may be the odd special character missing from an older page, it's a problem that developed when Interactive Tools upgraded to a new content management system.


Finfacts is Ireland's leading business information site and you are in its business news section.


Finfacts Homepage

Irish Share Prices

Euribor Daily Rates

Irish Economy

Global Income Per Capita

Global Cost of Living

Irish Tax - Income/Corporate

Global News

Bloomberg News

CNN Money

Cnet Tech News


Irish Independent

Irish Times

Irish Examiner

New York Times

Financial Times

Technology News




Content Management by interactivetools.com.

News : Irish Economy Last Updated: Jun 28, 2013 - 8:49 AM

Ireland spends 50% above the EU average per capita on drugs
By Finfacts Team
Jun 27, 2013 - 4:42 AM

Email this article
 Printer friendly page
Click here to enlarge. The use of GDP for Ireland in the right-hand chart, understates the real ratio.

The ESRI (Economic and Social Research Institute) today published a report on the prices of drugs/ pharmaceuticals. Last year, the Organisation for Economic Cooperation and Development (OECD) reported that in 2010, at €528, Ireland spent more on pharmaceuticals than any other European country on a per capita basis. This is 50% above the average across EU member states of €349.

Other countries with relatively high pharmaceutical expenditure include Germany (€492), Belgium (€479) and France (€468). At the other end of the scale, Romania spent only €164 per capita. Denmark, Estonia, Latvia and Poland are also among the countries that have relatively low pharmaceutical spending per capita, at less than 70% of the EU average.

Pharmaceutical expenditure accounted for almost a fifth (19%) of all health expenditure on average in EU member states and the total pharmaceutical bill across the European Union reached more than €190bn in 2010.

Today's ESRI report says the cost of in-patent and generic drugs in Ireland remains high despite some efforts by the Government to tackle the problem.

The report was commissioned by the Department of Health and the HSE, following a request from the bailout Troika.

Ireland's  prices are the highest in Europe for 9 out of 13 commonly used generic medicines and for in-patent drugs, Ireland is among the three most expensive European countries surveyed for 10 leading products.

The researchers compared factory gate prices and in 2008, the State's drugs bill of €1.6bn had an estimated factory gate value of €1bn.

Pharmacy margins have been cut since but they are likelier to be higher than in other European countries.

The use of generic drugs in Ireland have increased but because of payments/ inducements to generic manufacturers, they tend to be similar to that of the original branded drugs.

Not only is the State being gouged but individuals without a medical card are also caught.

In a decision earlier this month that is a setback for the pharmaceutical industry, the US Supreme Court ruled that antitrust regulators should be able to challenge the arrangements that allow drug makers to delay the sale of a generic drug. In deals known as “reverse payments” or “pay for delay,” brand-name drug makers facing a patent challenge from generic competitors pay them to temporarily stay out of the market. Last year, there were 40 patent-dispute settlements between brand-name and generic drug makers involving a payment to the generic firm and restricted sale of a generic medicine, according to the US Federal Trade Commission (FTC.) The agreements related to 31 brand name drugs with yearly US sales of more than $8.3bn, the agency said.

The ESRI report, Ireland: Pharmaceutical Prices, Prescribing Practices and Usage of Generics in a Comparative Context, [pdf] is authored by Aoife Brick, Paul K. Gorecki and Anne Nolan (ESRI).

The report assesses the level of pharmaceutical prices, the usage of generics and the prescribing practices of medical practitioners in Ireland in comparison with other EU member states and OECD countries.

It is based on the latest HSE data for Ireland and comparable data from other countries.

The key findings of the research are:

Pharmaceutical Prices
  • Relative to other EU Member States:
    • originator in-patent pharmaceutical prices are higher in Ireland;
    • originator off-patent pharmaceutical prices are lower in Ireland; and
    • generic pharmaceutical prices are higher in Ireland.
  • Comparisons were based on March 2013 prices of leading pharmaceuticals.

Generic Usage

  • The market share of generics for the leading pharmaceuticals in the GMS Scheme doubled between 2010 and 2012, to reach 50 per cent.
  • Increased generic penetration has not led, up until now, to substantial savings for the State or the cash-paying patient.
  • This reflects the fact that, in contrast to much of the EU, generic prices tend to be similar to those of the brand name manufacturer.

Prescribing Practices

  • Where prescribers in Ireland have a choice between different pharmaceuticals within the same therapeutic sub-group – statins, ACE inhibitors, and proton pump inhibitors, they tend to select the most expensive pharmaceutical product.
  • In contrast, prescribers In the UK tend to prescribe the least expensive pharmaceutical product within each of the three therapeutic sub-groups.
  • These three therapeutic sub groups accounted for nearly one fifth of spending by the State under the GMS Scheme in 2012.

Restructuring the Price Setting Mechanism

  • The Health (Pricing and Medical Goods) Act 2013, which was signed into law on 28 May 2013, holds out the possibility of radically changing the way in which pharmaceutical prices are set in Ireland.
  • Pharmacists will be able to select a lower-priced pharmaceutical product than that prescribed for the patient by a medical practitioner for interchangeable pharmaceutical products.
  • Lack of clarity and precision as to how prices will be set under the Health (Pricing and Medical Goods) Act 2013 means that it is not possible to predict with any certainty that originator and generic pharmaceutical prices in Ireland will fall vis-à-vis other countries.
  • The Act builds on a series of reforms that the State has introduced since the mid-2000s to reduce pharmaceutical prices and expenditure.

Patient Access Agreements

  • The research also highlights the increasing use of 'patient access agreements' (in Ireland and in other countries) as an alternative mechanism for setting pharmaceutical prices.
  • Under 'patient access agreements', prices are negotiated between the State and manufactures but kept confidential.
  • The increasing use of this mechanism should prompt a wider discussion about:
    • transparency; and
    • how the benefits of new pharmaceutical products should be evaluated.

Check out our subscription service, Finfacts Premium , at a low annual charge of €25.

Related Articles
Related Articles

© Copyright 2011 by Finfacts.com

Top of Page

Irish Economy
Latest Headlines
Finfacts launches new news site
Irish Farmers & Milk Prices: 'Shackles' off in April; Demanding safety-net in August
Irish pension managed funds returns at over 12% year-to-date in 2015
Irish chartered accountants' salary packages surge 13% in 12 months
Irish services PMI fastest rate since late 2006; Official data up only 2.4% in 12 months
Irish Economy: Tax €893m above target in year to July — €653m from corporation tax
Fact and Fiction: Time to review Ireland's economic statistics?
Irish M&A deals H1 2015: Dutch or UK firm acquires Irish firm for €32.6bn - they are both American
Irish manufacturing PMI strong in July
Irish Economy: Fall in GNP in Q1 2015; GDP rises
Irish Economy 2015: Central Bank lauds strong recovery; Time to start paying down debt
Irish Budget 2016: Ibec demands 20 tax cuts, spending and investment rises
Low pay in Ireland; Lowest social security & corporate taxes in Europe
Ireland vs Greece: Enda Kenny's false claims on growth, taxes and debt
Irish standard of living in 2014 below Euro Area average, Italian level; Prices 5th highest in EU28
Irish goods exports rose a record 30% in April - due to fake tax-related transactions
Mexican tall ship to sail into Dublin on June 17th
Irish industrial production up 20% in first four months of 2015; Construction down 2.6% in first quarter
Irish Economy 2015: ESRI slams return to boom-time pro-cyclical fiscal policy
Irish pension fund returns in average range 1.6% - 1.8% in May 2015
Irish service sector PMI remains strong; Tax avoidance clouds data
Ireland: Official unemployment rate at 9.8% in May; Broad rate at 19% — 440,000 people
Ireland: Fiscal Council warns of dodgy forecasts, no plan; OECD warns of new property bubble
Irish Public Finances: Tax revenue in first five months of 2015 €734m ahead of target
No simple measure of economic progress in Ireland: GDP & GNP defective
Irish manufacturing PMI rises in May; Production up unbelievable 45% in year to March!
ESRI says data volatility hinders Irish economic forecasting; Tax avoidance taboo cause
Ireland at 16 in international competitiveness ranking; US, Singapore and Hong Kong on top
Irish Economy 2015: Sectors to add 200,000 jobs?; Broad jobless rate at 19%
Irish Export Performance: Myths and reality - Ireland is a poor exporter
Irish Economy: 41,300 jobs added in 12 months to Q1 2015 - Construction up 19,600
China-Ireland: Economic relationship on a slow burn
Estonia, Austria, France, Ireland head global alcohol rankings
Irish Exchequer Returns: Tax receipts under target in April but ahead in year
Irish service sector PMI rose in April
Irish manufacturing PMI remained strong in April- includes overseas manufacturing
Irish Live Register + 90,000 activation scheme numbers at 439,000 in April
Ireland: Coalition drops 2018 full-employment target
Ireland Spring Statement: Noonan promises 200,000 net new jobs by 2018
Irish Economy 2015: Retail sales volume up 1.4% in month of March